Literature DB >> 7389423

Pharmacokinetics of metronidazole in healthy adult volunteers after tablets and suppositories.

T Bergan, E Arnold.   

Abstract

A cross-over study on metronidazole was carried out with 10 healthy adult volunteers who received tablets (250, 500 and 1,000 mg) and suppositories (500, 1,000 and 2,000 mg). The bioavailability of the suppositories was approximately 90% of the corresponding tablet dose as judged by area under the serum curves and amounts excreted in urine. The absorption was faster after the tablets. The mean curve peaks of unchanged metronidazole after the tablets occurred within 1 h and were 3.7 microgram/ml after 250 mg, 9.8 microgram/ml after 500 mg, and 11.8 microgram/ml after 1,000 mg. The suppositories rendered peaks of 5.5, 9,5 and 14.0 microgram/ml 4 h after doses of 500, 1,000 and 2,000 mg, respectively. In the dosage range 250-1,000 mg, the relationship between the dose and the total area under serum curves was similar for tablets and suppositories. Parts of the drug in serum and urine were antibacterially active metabolites. The mean recovery in urine within 36 h was 7-14% of the dose. The serum half-life of unchanged metronidazole (chemical assay) was 8.8-10.5 h. The terminal phase half-life of the total biologically active compound (microbiological assay) was 7.8-15.1 h.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7389423     DOI: 10.1159/000237911

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

1.  In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile.

Authors:  Tarun Mathur; Tarani Kanta Barman; Manoj Kumar; Diksha Singh; Ram Kumar; Manoj Kumar Khera; Makiko Yamada; Shin-Ichi Inoue; Dilip Jatashankar Upadhyay; Nobuhisa Masuda
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

3.  Comparative pharmacokinetics of metronidazole and tinidazole as influenced by administration route.

Authors:  J Mattila; P T Männistö; R Mäntylä; S Nykänen; U Lamminsivu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

5.  Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.

Authors:  Xin Wang; Tatiana N Nanovskaya; Ying Zhan; Susan M Abdel-Rahman; Marlo Jasek; Gary D V Hankins; Mahmoud S Ahmed
Journal:  J Matern Fetal Neonatal Med       Date:  2010-07-07

Review 6.  Rectal drug administration: clinical pharmacokinetic considerations.

Authors:  A G de Boer; F Moolenaar; L G de Leede; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

7.  Influence of dose and route of administration on disposition of metronidazole and its major metabolites.

Authors:  S Loft; M Døssing; H E Poulsen; J Sonne; K L Olesen; K Simonsen; P B Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  The penetration of metronidazole into synovial fluid.

Authors:  M A Sattar; M G Sankey; M I Cawley; C M Kaye; J E Holt
Journal:  Postgrad Med J       Date:  1982-01       Impact factor: 2.401

Review 9.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.